$NVNO
enVVeno Medical Corp

2024 Q4 Form 10-Q Financial Statement

#000149315224043100 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.311M
YoY Change 29.79%
% of Gross Profit
Research & Development $2.859M
YoY Change 2.18%
% of Gross Profit
Depreciation & Amortization $43.00K
YoY Change -28.33%
% of Gross Profit
Operating Expenses $6.170M
YoY Change 15.35%
Operating Profit -$6.170M
YoY Change 15.35%
Interest Expense $528.0K
YoY Change 50.86%
% of Operating Profit
Other Income/Expense, Net $528.0K
YoY Change 51.72%
Pretax Income -$5.642M
YoY Change 12.84%
Income Tax
% Of Pretax Income
Net Earnings -$5.642M
YoY Change 12.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.35
COMMON SHARES
Basic Shares Outstanding 17.54M shares 13.33M shares
Diluted Shares Outstanding 16.07M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.38M
YoY Change 88.25%
Cash & Equivalents $17.92M
Short-Term Investments $30.46M
Other Short-Term Assets $672.0K
YoY Change 29.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.05M
YoY Change 87.1%
LONG-TERM ASSETS
Property, Plant & Equipment $218.0K
YoY Change -43.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $31.00K
YoY Change -55.71%
Total Long-Term Assets $1.339M
YoY Change -28.66%
TOTAL ASSETS
Total Short-Term Assets $49.05M
Total Long-Term Assets $1.339M
Total Assets $50.39M
YoY Change 79.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $894.0K
YoY Change -47.41%
Accrued Expenses $1.335M
YoY Change 66.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.229M
YoY Change 9.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $791.0K
YoY Change -31.22%
Total Long-Term Liabilities $791.0K
YoY Change -31.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.229M
Total Long-Term Liabilities $791.0K
Total Liabilities $3.020M
YoY Change -5.0%
SHAREHOLDERS EQUITY
Retained Earnings -$145.6M
YoY Change 17.07%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.37M
YoY Change
Total Liabilities & Shareholders Equity $50.39M
YoY Change 79.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.642M
YoY Change 12.82%
Depreciation, Depletion And Amortization $43.00K
YoY Change -28.33%
Cash From Operating Activities -$4.276M
YoY Change 1.33%
INVESTING ACTIVITIES
Capital Expenditures $9.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $6.229M
YoY Change 39.98%
Cash From Investing Activities $6.220M
YoY Change 39.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.59M
YoY Change
NET CHANGE
Cash From Operating Activities -4.276M
Cash From Investing Activities 6.220M
Cash From Financing Activities 13.59M
Net Change In Cash 15.54M
YoY Change 6654.35%
FREE CASH FLOW
Cash From Operating Activities -$4.276M
Capital Expenditures $9.000K
Free Cash Flow -$4.285M
YoY Change 1.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
30464000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
672000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
49051000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1090000 usd
CY2024Q3 NVNO Security Deposits And Other Assets Noncurrent
SecurityDepositsAndOtherAssetsNoncurrent
31000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3020000 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001661053
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Trading Symbol
TradingSymbol
NVNO
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17536000 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17915000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3620000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
511000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
46923000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
218000 usd
CY2023Q4 us-gaap Assets
Assets
48635000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1064000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2435000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5349000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17127000 usd
CY2024Q3 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
6000 usd
CY2023Q3 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
156000 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
96000 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
567000 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
94000 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
44000 usd
us-gaap Interest Income Other
InterestIncomeOther
226000 usd
us-gaap Interest Income Other
InterestIncomeOther
128000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
528000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
348000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1537000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1093000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5642000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5001000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15590000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17867000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38325
dei Entity Registrant Name
EntityRegistrantName
enVVeno Medical Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0936180
dei Entity Address Address Line1
EntityAddressAddressLine1
70 Doppler
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
dei City Area Code
CityAreaCode
(949)
dei Local Phone Number
LocalPhoneNumber
261-2900
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
42792000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
334000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1347000 usd
CY2023Q4 NVNO Security Deposits And Other Assets Noncurrent
SecurityDepositsAndOtherAssetsNoncurrent
31000 usd
CY2024Q3 us-gaap Assets
Assets
50390000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1872000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1033000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
357000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
338000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2229000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1371000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
791000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17536000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17536000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13317000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13317000 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
192996000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
176236000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145626000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130036000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47370000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
46200000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50390000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48635000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2859000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2798000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8736000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10602000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3311000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2551000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8391000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8358000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6170000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18960000 usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
428000 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
148000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1215000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
398000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16067000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16067000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11231000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11231000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16063000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16063000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11231000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11231000 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
38418000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13591000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1003000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5642000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47370000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
28812000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1104000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5001000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24915000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
46200000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13591000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3123000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15590000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47370000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38729000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38729000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4053000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17867000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24915000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24915000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15590000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17867000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3123000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4052000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
149000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
165000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
257000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
247000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
96000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
567000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
118000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
43000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
8000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
839000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
484000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-254000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-236000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11733000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13885000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33420000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
24276000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
45844000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
38581000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12391000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14276000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13591000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13637000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14295000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
391000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3620000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4555000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17915000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4946000 usd
CY2024Q3 us-gaap Cash
Cash
48400000 usd
CY2024Q3 us-gaap Investments
Investments
48400000 usd
CY2024Q3 NVNO Working Capital
WorkingCapital
47300000 usd
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
14900000 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3400000 usd
CY2024Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
894000 usd
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
427000 usd
CY2024Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
446000 usd
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
478000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
532000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
128000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1872000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1033000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13300000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1400000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1000000.0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.02 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15399000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8760000 shares

Files In Submission

Name View Source Status
0001493152-24-043100-index-headers.html Edgar Link pending
0001493152-24-043100-index.html Edgar Link pending
0001493152-24-043100.txt Edgar Link pending
0001493152-24-043100-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nvno-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
nvno-20240930_cal.xml Edgar Link unprocessable
nvno-20240930_def.xml Edgar Link unprocessable
nvno-20240930_lab.xml Edgar Link unprocessable
nvno-20240930_pre.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending